Elicio Therapeutics Inc (ELTX)
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s lead candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine being evaluated in Phase II trials for seven Kirsten rat sarcoma viral oncogene homolog (KRAS) driver mutations. Elicio is also advancing ELI-007, an AMP peptide treatment candidate for BRAF-driven cancers, and ELI-008, a preclinical AMP peptide vaccine being studied for cancers expressing mutated tumor protein p53. Elicio Therapeutics is headquartered in Boston, Massachusetts, and its common stock is listed on NASDAQ under the ticker ELTX.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ELTX
|
$3
|
-2.4% Downside
|
Fair
|
$20
|
549.4% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 7, 2026
|
-1.5x
|
-41.3x
|
—
|
57.978 M
|
58.705 M
|
19.8%
|
56.5%
|
-18.7
|
—
|
95.8%
|
